Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment

J Rheumatol. 2002 Feb;29(2):282-7.

Abstract

Objective: To clarify the clinical features of systemic lupus erythematosus (SLE) complicated with pulmonary hypertension (PH) and to evaluate the efficacy of immunosuppressive treatment.

Methods: Case records were reviewed for 194 patients with SLE who were admitted to Aoyama Hospital of Tokyo Women's Medical University between 1992 and 1999. There were 12 patients with PH [8 SLE and 4 SLE + systemic sclerosis (SSc) overlap syndrome]. These patients were compared with 59 age and sex matched patients with SLE for clinical characteristics and laboratory findings. The efficacy of treatments for PH was also evaluated.

Results: In our cohort of 194 patients with SLE, 6.2% had PH. The plasma thrombin-antithrombin III complex and plasma D-dimer levels were significantly higher in patients with PH compared with those without PH. Eight patients with PH (4 SLE and 4 SLE + SSc) were treated with corticosteroids (CS) +/- cyclophosphamide (CYC). Right ventricular systolic pressure (RVSP) was improved in 7 of 8 patients. In 6 of 7 responders to the therapy, the treatment was started as soon as they were diagnosed with PH. PH relapsed in 2 patients treated with oral CS +/- CS pulse therapy, but their RVSP was decreased again by immunosuppressive treatment.

Conclusion: CS +/- CYC was effective for PH associated with SLE. Immunosuppressive treatment should be performed during the early stage of PH to improve prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antithrombin III / immunology
  • Antithrombin III / metabolism
  • Cohort Studies
  • Cyclophosphamide / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Fibrin Fibrinogen Degradation Products / immunology
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Glucocorticoids / therapeutic use*
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / physiopathology
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / physiopathology
  • Male
  • Middle Aged
  • Treatment Outcome
  • Ventricular Dysfunction, Right / drug therapy
  • Ventricular Dysfunction, Right / physiopathology

Substances

  • Fibrin Fibrinogen Degradation Products
  • Glucocorticoids
  • Immunosuppressive Agents
  • fibrin fragment D
  • Cyclophosphamide
  • Antithrombin III